Your browser doesn't support javascript.
loading
Performance of novel antibodies for lipoarabinomannan to develop diagnostic tests for Mycobacterium tuberculosis.
Cantera, Jason L; Lillis, Lorraine M; Peck, Roger B; Moreau, Emmanuel; Schouten, James A; Davis, Paul; Drain, Paul K; Andama, Alfred; Pinter, Abraham; Kawasaki, Masanori; Källenius, Gunilla; Sundling, Christopher; Dobos, Karen M; Flores, Danara; Chatterjee, Delphi; Murphy, Eileen; Halas, Olivia R; Boyle, David S.
Afiliação
  • Cantera JL; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Lillis LM; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Peck RB; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Moreau E; TB Program, FIND, Geneva, Switzerland.
  • Schouten JA; Mologic, Thurleigh, Beds, United Kingdom.
  • Davis P; Mologic, Thurleigh, Beds, United Kingdom.
  • Drain PK; Departments of Global Health, Medicine, and Epidemiology, University of Washington, Seattle, Washington, United States of America.
  • Andama A; College of Health Sciences, Makerere University, Kampala, Uganda.
  • Pinter A; Public Health Research Institute Center, New Jersey Medical School, Rutgers University, New Brunswick, New Jersey, United States of America.
  • Kawasaki M; Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan.
  • Källenius G; Division of Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet and Department of Infectious Diseases, Karolinska University Hospital, Solna, Sweden.
  • Sundling C; Division of Infectious Diseases, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet and Department of Infectious Diseases, Karolinska University Hospital, Solna, Sweden.
  • Dobos KM; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
  • Flores D; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
  • Chatterjee D; Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, United States of America.
  • Murphy E; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Halas OR; Diagnostics Program, PATH, Seattle, Washington, United States of America.
  • Boyle DS; Diagnostics Program, PATH, Seattle, Washington, United States of America.
PLoS One ; 17(9): e0274415, 2022.
Article em En | MEDLINE | ID: mdl-36178936
ABSTRACT
Lipoarabinomannan (LAM), a component of the Mycobacterium tuberculosis (MTB) cell wall, is detectable in the urine of MTB infected patients with active tuberculosis (TB). LAM-specific antibodies (Igs) have been developed by a variety of traditional and recombinant methods for potential use in a rapid diagnostic test (RDT). We evaluated the analytical performance of the TB LAM Igs to identify pairs that offer superior performance over existing urine LAM tests. We assessed 25 new and 4 existing Igs in a matrixed format using a multiplex electrochemiluminescence-based liquid immunoassay. A total of 841 paired Ig combinations were challenged with in vitro cultured LAM (cLAM) derived from MTB strains representing diverse phylogenetic lineages, alongside urinary LAM (uLAM) from the urine of adults with active pulmonary TB. Analytical sensitivity of down-selected Ig pairs was determined using MTB Aoyama-B cLAM, while diagnostic accuracy was determined using clinical samples. When testing cLAM, the reactivity of Ig pairs was similar across MTB lineages 1-4 but lineage 56 had significantly more reactivity among Ig pairs. Overall, 41 Ig pairs had a strong binding affinity to cLAM, as compared to the reference pair of S4-20/A194-01, and 28 Ig pairs therein exhibited a strong affinity for both cLAM and uLAM. Retrospective testing on clinical urine specimens demonstrated varying sensitivities (12-80%) and specificities (14-100%). The five top pairs had a similar analytical limit of detection to the reference pair but in four instances, the sensitivity and specificity with clinical uLAM samples was poor. Overall, epitopes presented by uLAM are different from cLAM, which may affect antibody performance when testing uLAM in patient samples. Several new Ig pairs had similar ranges of high sensitivity to cLAM but overall, there were no new candidate Ig pairs identified in this round of screening with increased performance with uLAM as compared to an existing optimal pair.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose dos Linfonodos / Infecções por HIV / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tuberculose dos Linfonodos / Infecções por HIV / Mycobacterium tuberculosis Idioma: En Ano de publicação: 2022 Tipo de documento: Article